机构:[1]Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215004, China[2]Department of Emergency, Shanxi Provincial People’s Hospital, Taiyuan 030001, China[3]Department of Neurology, Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215004, China[4]Department of Pharmaceutical Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA[5]The Central Laboratory, Shenzhen Second People’s Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen 518035, China
N-acetylcysteine (NAC), a precursor of glutathione that reduces reperfusion-induced injury, has been shown protection when it was administered pre-ischemia. However, less is known about the effect when it was given post-ischemia and there is no positive result associated with anti-oxidant in clinical trials. This study investigated the neuro- and vaso-protection of post-ischemia NAC administration as well as combining NAC with normobaric hyperoxia (NBO). Male Sprague-Dawley rats were exposed to NBO or normoxia during 2-h occlusion of the middle cerebral artery, followed by 48-h reperfusion. NAC or vehicle was intraperitoneally administered to rats immediately before reperfusion onset. NAC and NBO treatments produced 1.2 and 30 % reduction of infarction volume, respectively, and combination treatment showed greater reduction (59.8 %) as well as more decrease of hemispheric swelling volume. Of note, combination therapy showed improved neurological assessment and motor function which were sustained for 7 days after reperfusion. We also determined that the combination therapy showed greater inhibitory effects on tight junction protein degradation accompanied by Evan's blue extravasation, hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) induction, and poly ADP-ribose polymerase (PARP)-1 activation in ischemic brain tissue. Our results showed that although post-ischemia NAC administration had limited protection, combination treatment of NAC plus NBO effectively prevented blood-brain barrier (BBB) damage and significantly improved the outcome of brain injury, providing new evidence to support the concept that "cocktail" treatment targeting different stages provides better neuro- and vaso-protection than current individual treatment that has all failed in their clinical trials.
基金:
This work was supported by Soochow University Research
starting funds (Q 421500113), by Fund of Ministry of Education of China
(K521507713), and by Shenzhen Science and Technology Innovation
C o m m i s s i o n ( C X Z Z 2 0 1 3 0 5 1 6 1 5 2 7 0 6 0 4 0 a n d
ZDSY20140509173142601). This work was supported by A Project by
the Priority Academic Program Development of Jiangsu Higher
Education Institutions of China.
第一作者机构:[1]Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215004, China
共同第一作者:
通讯作者:
通讯机构:[1]Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215004, China
推荐引用方式(GB/T 7714):
Yushan Liu,Wen-Cao Liu,Yanyun Sun,et al.Normobaric Hyperoxia Extends Neuro- and Vaso-Protection of N-Acetylcysteine in Transient Focal Ischemia[J].MOLECULAR NEUROBIOLOGY.2017,54(5):3418-3427.doi:10.1007/s12035-016-9932-0.
APA:
Yushan Liu,Wen-Cao Liu,Yanyun Sun,Xianzhi Shen,Xiaona Wang...&Xinchun Jin.(2017).Normobaric Hyperoxia Extends Neuro- and Vaso-Protection of N-Acetylcysteine in Transient Focal Ischemia.MOLECULAR NEUROBIOLOGY,54,(5)
MLA:
Yushan Liu,et al."Normobaric Hyperoxia Extends Neuro- and Vaso-Protection of N-Acetylcysteine in Transient Focal Ischemia".MOLECULAR NEUROBIOLOGY 54..5(2017):3418-3427